Category: Press Release - Page 96 - Psychedelic Alpha

Read more about the article Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Post published:October 19, 2021
Post category:Press Release

Read more about the article First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Post published:October 19, 2021
Post category:Press Release

Read more about the article PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

Post published:October 19, 2021
Post category:Press Release

Read more about the article COMPASS Pathways is granted new US patent for crystalline psilocybin

COMPASS Pathways is granted new US patent for crystalline psilocybin

Post published:October 19, 2021
Post category:Press Release

Read more about the article atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

Post published:October 19, 2021
Post category:Press Release

Read more about the article Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Post published:October 14, 2021
Post category:Press Release

Read more about the article Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

Post published:October 14, 2021
Post category:Press Release

Read more about the article Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Post published:October 13, 2021
Post category:Press Release

Read more about the article MindMed Joins Clinical Trials Transformation Initiative

MindMed Joins Clinical Trials Transformation Initiative

Post published:October 13, 2021
Post category:Press Release

Read more about the article PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

Post published:October 13, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.